These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 9132763)

  • 21. Acute weight gain induced by amisulpride monotherapy in a first-episode schizophrenic patient.
    Papadimitriou GN; Theleritis CG; Dikeos DG; Psarros CJ; Soldatos CR
    Int Clin Psychopharmacol; 2006 May; 21(3):181-4. PubMed ID: 16528141
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia.
    Roth BL; Sheffler DJ; Kroeze WK
    Nat Rev Drug Discov; 2004 Apr; 3(4):353-9. PubMed ID: 15060530
    [No Abstract]   [Full Text] [Related]  

  • 23. [Antipsychotic agents in the treatment of somatoform disorders; a review].
    Decoutere L; van den Eede F; Moorkens G; Sabbe BG
    Tijdschr Psychiatr; 2011; 53(3):163-73. PubMed ID: 21404173
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Sulpiride: the best known atypical, safe neuroleptic drug. Review of literature].
    Rzewuska M
    Psychiatr Pol; 1998; 32(5):655-66. PubMed ID: 9921002
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment-emergent tardive dyskinesia with quetiapine in mood disorders.
    Sharma V
    J Clin Psychopharmacol; 2003 Aug; 23(4):415-7. PubMed ID: 12920421
    [No Abstract]   [Full Text] [Related]  

  • 26. Weight gain in a patient with schizophrenia switched from quetiapine to amisulpride.
    Chen YY; Huang MC; Wu KC
    Psychiatry Clin Neurosci; 2008 Oct; 62(5):620-1. PubMed ID: 18950385
    [No Abstract]   [Full Text] [Related]  

  • 27. Somatic-type delusional disorder: a case report and comments.
    Kepska A; Hawro T; Krupinska-Kun M; Zalewska A
    Acta Derm Venereol; 2011 Mar; 91(2):193-4. PubMed ID: 21031280
    [No Abstract]   [Full Text] [Related]  

  • 28. Augmentation of clozapine with amisulpride: a promising therapeutic approach to refractory schizophrenic symptoms.
    Kämpf P; Agelink MW; Naber D
    Pharmacopsychiatry; 2005 Jan; 38(1):39-40. PubMed ID: 15706467
    [No Abstract]   [Full Text] [Related]  

  • 29. Tardive dystonia associated with low-dose of amisulpride: a case report.
    Sevincok L; Balci V; Akyildiz U
    J Clin Psychopharmacol; 2008 Oct; 28(5):573-4. PubMed ID: 18794659
    [No Abstract]   [Full Text] [Related]  

  • 30. [Sulpiride (Dogmatil). A new antipsychosis agent (neuroleptic) with few side effects].
    Gerlach J
    Ugeskr Laeger; 1983 Aug; 145(34):2611-2. PubMed ID: 6137095
    [No Abstract]   [Full Text] [Related]  

  • 31. [Early-stage schizophrenia in cases of committed suicide].
    Nakayasu N; Seki Y
    Seishin Shinkeigaku Zasshi; 2005; 107(10):1078-85. PubMed ID: 16381391
    [No Abstract]   [Full Text] [Related]  

  • 32. Improvement of amisulpride-induced extrapyramidal symptoms with quetiapine.
    Jagadheesan K; Muirhead D
    Aust N Z J Psychiatry; 2004 Jul; 38(7):560. PubMed ID: 15255830
    [No Abstract]   [Full Text] [Related]  

  • 33. Antidepressants and somatic symptoms: therapeutic actions are expanding beyond affective spectrum disorders to functional somatic syndromes.
    Stahl SM
    J Clin Psychiatry; 2003 Jul; 64(7):745-6. PubMed ID: 12934972
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Amisulpride doses and plasma levels in different age groups of patients with schizophrenia or schizoaffective disorder.
    Müller MJ; Eich FX; Regenbogen B; Sachse J; Härtter S; Hiemke C
    J Psychopharmacol; 2009 May; 23(3):278-86. PubMed ID: 18562411
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Psychopharmacologic issues in the maintenance treatment of schizophrenia.
    Kane JM; Borenstein M; Woerner M
    Psychopharmacol Bull; 1984; 20(3):423-5. PubMed ID: 6147875
    [No Abstract]   [Full Text] [Related]  

  • 36. Efficacy of atypical antipsychotics in mood disorders.
    Yatham LN
    J Clin Psychopharmacol; 2003 Jun; 23(3 Suppl 1):S9-14. PubMed ID: 12832944
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Therapeutic and side effects of treatment with sulpiride].
    Goldwurm GF; Peghini R
    Agressologie; 1978; 19(C):157-64. PubMed ID: 375762
    [No Abstract]   [Full Text] [Related]  

  • 38. Sulpiride: evaluation of antipsychotic activity in chronic schizophrenic patients.
    Mielke DH; Gallant DM; Roniger JJ; Kessler C
    Psychopharmacol Bull; 1977 Jul; 13(3):40-1. PubMed ID: 18758
    [No Abstract]   [Full Text] [Related]  

  • 39. [Betamax (sulpirid): potential for clinical application].
    Ivanov SV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(12):83-7. PubMed ID: 22433816
    [No Abstract]   [Full Text] [Related]  

  • 40. [Clinical-neuroleptic investigation of N-((1-ethyl-pyrrolidine-2-yl)-methyl)-2-methoxy-5-sulfamyl-benzamide-neuroleptic sulpiride (Dogmatil) in acutly ill schizophrenics].
    Haase HJ; Floru L; Ulrich F
    Int Pharmacopsychiatry; 1974; 9(2):77-94. PubMed ID: 4603413
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.